Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Provided By GlobeNewswire
Last update: Feb 14, 2025
-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025-
-Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025-
Read more at globenewswire.comNASDAQ:BNTC (12/5/2025, 11:16:27 AM)
12.87
-0.31 (-2.35%)
Find more stocks in the Stock Screener
